PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30186866-13	2018	Additionally, TNF-alpha protein levels in BALF and lung tissue were diminished by levocetirizine administration.	levocetirizine	82-96	tumor necrosis factor	Rattus norvegicus	14-23
28653802-11	2017	We found a significant associations for several drug-reaction pairs such as levocetirizine and epilepsy (ROR, 6.57; 95% confidence interval [CI], 1.51-28.53) and chlorphenamine and toxic epidermal necrolysis (ROR, 7.29; 95% CI, 2.39-22.2).	levocetirizine	76-90	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	105-108
28653802-11	2017	We found a significant associations for several drug-reaction pairs such as levocetirizine and epilepsy (ROR, 6.57; 95% confidence interval [CI], 1.51-28.53) and chlorphenamine and toxic epidermal necrolysis (ROR, 7.29; 95% CI, 2.39-22.2).	levocetirizine	76-90	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	209-212
26740893-15	2015	Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1beta and IL-8.	levocetirizine	0-14	interleukin 1 beta	Homo sapiens	86-94
27758758-10	2017	In LAD2, rupatadine (5 and 10 microM) and levocetirizine (5 microM), but not desloratadine, inhibited PAF-induced b-hexosaminidase release.	levocetirizine	42-56	PCNA clamp associated factor	Homo sapiens	102-105
27758758-11	2017	Rupatadine (1-10 microM), levocetirizine (1-10 microM), and desloratadine (10 microM) inhibited PAF-induced histamine release.	levocetirizine	26-40	PCNA clamp associated factor	Homo sapiens	96-99
27758758-13	2017	CONCLUSIONS: This study shows that rupatadine and, to a lesser extent, levocetirizine, but not desloratadine, inhibit PAF-induced degranulation in both LAD2 and hLMCs.	levocetirizine	71-85	PCNA clamp associated factor	Homo sapiens	118-121
27012991-9	2016	Moreover, levocetirizine attenuated the elevated renal levels of TNF-alpha and TGF-beta1, ameliorated renal oxidative stress and restored NO bioavailability in diabetic kidney.	levocetirizine	10-24	tumor necrosis factor	Rattus norvegicus	65-74
27012991-9	2016	Moreover, levocetirizine attenuated the elevated renal levels of TNF-alpha and TGF-beta1, ameliorated renal oxidative stress and restored NO bioavailability in diabetic kidney.	levocetirizine	10-24	transforming growth factor, beta 1	Rattus norvegicus	79-88
28385546-0	2017	Cellular Uptake of Levocetirizine by Organic Anion Transporter 4.	levocetirizine	19-33	solute carrier family 22 member 11	Homo sapiens	37-64
28385546-2	2017	In this study, we aimed to investigate the transport mechanism of levocetirizine, the pharmacologically active enantiomer of cetirizine, via human organic anion transporter 4 (OAT4) expressed in the apical membrane of renal proximal tubules and the basal plasma membrane of placental syncytiotrophoblasts.	levocetirizine	66-80	solute carrier family 22 member 11	Homo sapiens	147-174
28385546-2	2017	In this study, we aimed to investigate the transport mechanism of levocetirizine, the pharmacologically active enantiomer of cetirizine, via human organic anion transporter 4 (OAT4) expressed in the apical membrane of renal proximal tubules and the basal plasma membrane of placental syncytiotrophoblasts.	levocetirizine	66-80	solute carrier family 22 member 11	Homo sapiens	176-180
28385546-3	2017	In cells expressing human OAT4 under the control of tetracycline, levocetirizine uptake was increased by tetracycline treatment.	levocetirizine	66-80	solute carrier family 22 member 11	Homo sapiens	26-30
28385546-5	2017	The OAT4-mediated levocetirizine uptake was concentration-dependent with a Km of 38 muM.	levocetirizine	18-32	solute carrier family 22 member 11	Homo sapiens	4-8
28385546-5	2017	The OAT4-mediated levocetirizine uptake was concentration-dependent with a Km of 38 muM.	levocetirizine	18-32	latexin	Homo sapiens	84-87
28385546-6	2017	The uptake rate of levocetirizine via OAT4 was approximately twice that of racemic cetirizine, indicating stereoselective uptake of levocetirizine.	levocetirizine	19-33	solute carrier family 22 member 11	Homo sapiens	38-42
28385546-6	2017	The uptake rate of levocetirizine via OAT4 was approximately twice that of racemic cetirizine, indicating stereoselective uptake of levocetirizine.	levocetirizine	132-146	solute carrier family 22 member 11	Homo sapiens	38-42
28385546-7	2017	On the other hand, OAT4-mediated [3H]dehydroepiandrosterone sulfate uptake was inhibited by dextrocetirizine and levocetirizine.	levocetirizine	113-127	solute carrier family 22 member 11	Homo sapiens	19-23
28385546-8	2017	Overall, our findings indicate that OAT4 mediates levocetirizine uptake but is unlikely to mediate the efflux.	levocetirizine	50-64	solute carrier family 22 member 11	Homo sapiens	36-40
28070872-1	2017	INTRODUCTION: As a substrate of P-glycoprotein, levocetirizine should not cause sedative effects.	levocetirizine	48-62	ATP binding cassette subfamily B member 1	Homo sapiens	32-46
26740893-15	2015	Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1beta and IL-8.	levocetirizine	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	99-103
23562192-0	2013	Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine.	levocetirizine	177-191	intercellular adhesion molecule 1	Homo sapiens	37-70
25466429-0	2015	Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine.	levocetirizine	83-97	histamine receptor H1	Homo sapiens	6-27
25064340-6	2014	Treatment with levocetirizine caused significant decreases in AUCOGTT, AUCITT, HOMA-IR, hepatic GSH and MDA levels and serum CRP level and LDH activity and significant increases in hepatic SOD activity and HOMA-beta when compared with the HFD group.	levocetirizine	15-29	C-reactive protein	Rattus norvegicus	125-128
24982238-0	2014	Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo.	levocetirizine	21-35	C-C motif chemokine ligand 5	Homo sapiens	85-91
24982238-0	2014	Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo.	levocetirizine	21-35	C-C motif chemokine ligand 11	Homo sapiens	96-103
24982238-8	2014	The addition of levocetirizine to eosinophil cultures caused a dose-dependent decrease in the ability of cells to produce RANTES and eotaxin in response to antigen stimulation, and the minimum concentration that caused a significant decrease was 0.05 muM.	levocetirizine	16-30	C-C motif chemokine ligand 5	Homo sapiens	122-128
24982238-8	2014	The addition of levocetirizine to eosinophil cultures caused a dose-dependent decrease in the ability of cells to produce RANTES and eotaxin in response to antigen stimulation, and the minimum concentration that caused a significant decrease was 0.05 muM.	levocetirizine	16-30	C-C motif chemokine ligand 11	Homo sapiens	133-140
24982238-8	2014	The addition of levocetirizine to eosinophil cultures caused a dose-dependent decrease in the ability of cells to produce RANTES and eotaxin in response to antigen stimulation, and the minimum concentration that caused a significant decrease was 0.05 muM.	levocetirizine	16-30	latexin	Homo sapiens	251-254
24982238-10	2014	Oral administration of levocetirizine for four weeks also reduced RANTES and eotaxin levels in nasal secretions from patients with pollinosis, along with attenuation of clinical symptoms.	levocetirizine	23-37	C-C motif chemokine ligand 5	Homo sapiens	66-72
24982238-10	2014	Oral administration of levocetirizine for four weeks also reduced RANTES and eotaxin levels in nasal secretions from patients with pollinosis, along with attenuation of clinical symptoms.	levocetirizine	23-37	C-C motif chemokine ligand 11	Homo sapiens	77-84
24982238-11	2014	The ability of levocetirizine to reduce RANTES and eotaxin levels may account, at least in part, for the clinical efficacy of the agent for allergic disorders, including allergic rhinitis.	levocetirizine	15-29	C-C motif chemokine ligand 5	Homo sapiens	40-46
24982238-11	2014	The ability of levocetirizine to reduce RANTES and eotaxin levels may account, at least in part, for the clinical efficacy of the agent for allergic disorders, including allergic rhinitis.	levocetirizine	15-29	C-C motif chemokine ligand 11	Homo sapiens	51-58
24499312-2	2013	We aimed to assess the anti-PAF effects of rupatadine and levocetirizine in the upper airways.	levocetirizine	58-72	PCNA clamp associated factor	Homo sapiens	28-31
24499312-5	2013	In SAR patients but not in HV, both rupatadine and levocetirizine showed a trend to decrease PAF-induced T4SS from 60 to 120 minutes.	levocetirizine	51-65	PCNA clamp associated factor	Homo sapiens	93-96
29025467-0	2013	Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine.	levocetirizine	177-191	intercellular adhesion molecule 1	Homo sapiens	37-70
22994340-8	2012	From the data reviewed in this article, especially the direct comparative data of desloratadine and levocetirizine in weal and flare studies and CSU, weal and flare response would appear to be the best indicator we have of effectiveness of H(1)-antihistamines in clinical practice.	levocetirizine	100-114	H1.5 linker histone, cluster member	Homo sapiens	240-244
24490170-0	2013	Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro.	levocetirizine	40-54	secreted phosphoprotein 1	Homo sapiens	15-26
24490170-0	2013	Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro.	levocetirizine	40-54	histamine receptor H1	Homo sapiens	58-79
22185747-3	2011	We investigated the inhibitory effects of levocetirizine (LCT) on the RV-induced expression of (1) fibrogenic (MMPs and TGF-beta) and (2) angiogenic (VEGF and TGF-beta) factors in NP fibroblasts.	levocetirizine	58-61	matrix metallopeptidase 2	Homo sapiens	111-115
22192965-3	2012	Recent studies have demonstrated that Levocetirizine (LCT) has anti-inflammatory properties that are mediated by inhibitory effects on NF-kappaB in addition to classic antihistaminic effects.	levocetirizine	38-52	nuclear factor kappa B subunit 1	Homo sapiens	135-144
22192965-3	2012	Recent studies have demonstrated that Levocetirizine (LCT) has anti-inflammatory properties that are mediated by inhibitory effects on NF-kappaB in addition to classic antihistaminic effects.	levocetirizine	54-57	nuclear factor kappa B subunit 1	Homo sapiens	135-144
23284599-1	2012	UNLABELLED: BACKGROUND #ENTITYSTARTX00026; PURPOSE: Levocetirizine is a histamine H(1) receptor antagonist.	levocetirizine	52-66	histamine receptor H1	Mus musculus	72-95
22185747-3	2011	We investigated the inhibitory effects of levocetirizine (LCT) on the RV-induced expression of (1) fibrogenic (MMPs and TGF-beta) and (2) angiogenic (VEGF and TGF-beta) factors in NP fibroblasts.	levocetirizine	58-61	transforming growth factor beta 1	Homo sapiens	120-128
20014242-6	2010	R-cetirizine significantly increased the efflux ratio of rhodamine-123 and doxorubicin in a fashion indicative of the upregulation of P-gp and MRP activities.	levocetirizine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
21330073-9	2011	The expression of TRIF and RIP, measured by Western blot, was decreased by pretreatment with LCEZ.	levocetirizine	93-97	TIR domain containing adaptor molecule 1	Homo sapiens	18-22
21330073-0	2011	Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP).	levocetirizine	0-13	toll like receptor 3	Homo sapiens	72-77
21330073-0	2011	Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP).	levocetirizine	0-13	interferon beta 1	Homo sapiens	164-172
21330073-0	2011	Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP).	levocetirizine	0-13	TIR domain containing adaptor molecule 1	Homo sapiens	174-178
21330073-0	2011	Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP).	levocetirizine	0-13	receptor interacting serine/threonine kinase 1	Homo sapiens	184-212
21330073-0	2011	Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP).	levocetirizine	0-13	receptor interacting serine/threonine kinase 1	Homo sapiens	214-217
21330073-1	2011	OBJECTIVE: To investigate the anti-inflammatory effect of levocetrizine (LCEZ) on the intracellular adhesion molecule-1 (ICAM-1) in human nasal epithelial cells stimulated by TLR3 and further analyze the anti-inflammatory mechanism of LCEZ in the MyD88-independent pathway before NF-kappaB is activated.	levocetirizine	58-71	intercellular adhesion molecule 1	Homo sapiens	86-119
21330073-1	2011	OBJECTIVE: To investigate the anti-inflammatory effect of levocetrizine (LCEZ) on the intracellular adhesion molecule-1 (ICAM-1) in human nasal epithelial cells stimulated by TLR3 and further analyze the anti-inflammatory mechanism of LCEZ in the MyD88-independent pathway before NF-kappaB is activated.	levocetirizine	58-71	intercellular adhesion molecule 1	Homo sapiens	121-127
21330073-1	2011	OBJECTIVE: To investigate the anti-inflammatory effect of levocetrizine (LCEZ) on the intracellular adhesion molecule-1 (ICAM-1) in human nasal epithelial cells stimulated by TLR3 and further analyze the anti-inflammatory mechanism of LCEZ in the MyD88-independent pathway before NF-kappaB is activated.	levocetirizine	58-71	MYD88 innate immune signal transduction adaptor	Homo sapiens	247-252
21330073-1	2011	OBJECTIVE: To investigate the anti-inflammatory effect of levocetrizine (LCEZ) on the intracellular adhesion molecule-1 (ICAM-1) in human nasal epithelial cells stimulated by TLR3 and further analyze the anti-inflammatory mechanism of LCEZ in the MyD88-independent pathway before NF-kappaB is activated.	levocetirizine	73-77	intercellular adhesion molecule 1	Homo sapiens	86-119
21330073-1	2011	OBJECTIVE: To investigate the anti-inflammatory effect of levocetrizine (LCEZ) on the intracellular adhesion molecule-1 (ICAM-1) in human nasal epithelial cells stimulated by TLR3 and further analyze the anti-inflammatory mechanism of LCEZ in the MyD88-independent pathway before NF-kappaB is activated.	levocetirizine	73-77	intercellular adhesion molecule 1	Homo sapiens	121-127
21330073-1	2011	OBJECTIVE: To investigate the anti-inflammatory effect of levocetrizine (LCEZ) on the intracellular adhesion molecule-1 (ICAM-1) in human nasal epithelial cells stimulated by TLR3 and further analyze the anti-inflammatory mechanism of LCEZ in the MyD88-independent pathway before NF-kappaB is activated.	levocetirizine	73-77	toll like receptor 3	Homo sapiens	175-179
21330073-8	2011	Pretreatment with LCEZ decreased the secretion of ICAM-1, which was observed in RT-PCR and Western blots but not in ELISA analyses.	levocetirizine	18-22	intercellular adhesion molecule 1	Homo sapiens	50-56
21330073-9	2011	The expression of TRIF and RIP, measured by Western blot, was decreased by pretreatment with LCEZ.	levocetirizine	93-97	receptor interacting serine/threonine kinase 1	Homo sapiens	27-30
21091390-0	2011	Improving SAR symptoms with levocetirizine: evaluating active and placebo effects in pollen challenge vs. natural exposure studies.	levocetirizine	28-42	sarcosine dehydrogenase	Homo sapiens	10-13
20014242-6	2010	R-cetirizine significantly increased the efflux ratio of rhodamine-123 and doxorubicin in a fashion indicative of the upregulation of P-gp and MRP activities.	levocetirizine	0-12	ATP binding cassette subfamily C member 3	Homo sapiens	143-146
18926057-3	2008	The aim of this study was to investigate the effects of these two antihistamines (cetirizine and levocetirizine) on granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-8 secretion in A549 human airway epithelial cells.	levocetirizine	97-111	colony stimulating factor 2	Homo sapiens	116-164
19857990-0	2009	Study on the interaction of levocetirizine dihydrochloride with human serum albumin by molecular spectroscopy.	levocetirizine	28-58	albumin	Homo sapiens	70-83
18946193-4	2008	Levocetirizine treatment also correlated with a significant increase in the percentage of CD4+CD25+ T cells (P<0.001).	levocetirizine	0-14	CD4 molecule	Homo sapiens	90-93
18946193-5	2008	The ability of levocetirizine to reduce percentage representation of cell phenotypes known to contribute to inflammatory tissue damage (eosinophils, CD4+CD29+, CD4+CD212+, and CD4+CD54+) and expand percentages of CD4+CD25+, which may include protective immunoregulatory (Treg) cells, indicates that the drug has pharmacological potential beyond the immediate effects of H(1) histamine-receptor inhibition.	levocetirizine	15-29	CD4 molecule	Homo sapiens	149-152
18946193-5	2008	The ability of levocetirizine to reduce percentage representation of cell phenotypes known to contribute to inflammatory tissue damage (eosinophils, CD4+CD29+, CD4+CD212+, and CD4+CD54+) and expand percentages of CD4+CD25+, which may include protective immunoregulatory (Treg) cells, indicates that the drug has pharmacological potential beyond the immediate effects of H(1) histamine-receptor inhibition.	levocetirizine	15-29	CD4 molecule	Homo sapiens	160-163
18946193-5	2008	The ability of levocetirizine to reduce percentage representation of cell phenotypes known to contribute to inflammatory tissue damage (eosinophils, CD4+CD29+, CD4+CD212+, and CD4+CD54+) and expand percentages of CD4+CD25+, which may include protective immunoregulatory (Treg) cells, indicates that the drug has pharmacological potential beyond the immediate effects of H(1) histamine-receptor inhibition.	levocetirizine	15-29	CD4 molecule	Homo sapiens	160-163
18946193-5	2008	The ability of levocetirizine to reduce percentage representation of cell phenotypes known to contribute to inflammatory tissue damage (eosinophils, CD4+CD29+, CD4+CD212+, and CD4+CD54+) and expand percentages of CD4+CD25+, which may include protective immunoregulatory (Treg) cells, indicates that the drug has pharmacological potential beyond the immediate effects of H(1) histamine-receptor inhibition.	levocetirizine	15-29	CD4 molecule	Homo sapiens	160-163
18926057-3	2008	The aim of this study was to investigate the effects of these two antihistamines (cetirizine and levocetirizine) on granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-8 secretion in A549 human airway epithelial cells.	levocetirizine	97-111	colony stimulating factor 2	Homo sapiens	166-172
18926057-3	2008	The aim of this study was to investigate the effects of these two antihistamines (cetirizine and levocetirizine) on granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-8 secretion in A549 human airway epithelial cells.	levocetirizine	97-111	C-X-C motif chemokine ligand 8	Homo sapiens	178-196
18926057-6	2008	Our data showed that cetirizine (5 and 10 microM) and levocetirizine (2.5, 5, and 10 microM) significantly suppressed GM-CSF secretion from A549 cells stimulated with IL-1beta (p<0.05).	levocetirizine	54-68	colony stimulating factor 2	Homo sapiens	118-124
18926057-6	2008	Our data showed that cetirizine (5 and 10 microM) and levocetirizine (2.5, 5, and 10 microM) significantly suppressed GM-CSF secretion from A549 cells stimulated with IL-1beta (p<0.05).	levocetirizine	54-68	interleukin 1 beta	Homo sapiens	167-175
18926057-7	2008	Cetirizine (10 microM) and levocetirizine (5 and 10 microM) significantly suppressed IL-8 secretion after A549 was stimulated.	levocetirizine	27-41	C-X-C motif chemokine ligand 8	Homo sapiens	85-89
18926057-9	2008	Moreover, levocetirizine, 5 microM, was better than cetirizine, 5 microM, on suppressing IL-8 secretion, but such a difference did not appear in other conditions.	levocetirizine	10-24	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
18926057-10	2008	Our results suggest that cetirizine and levocetirizine at higher concentrations can reduce the release of GM-CSF and IL-8 from A549 cells stimulated with IL-1beta.	levocetirizine	40-54	colony stimulating factor 2	Homo sapiens	106-112
18926057-10	2008	Our results suggest that cetirizine and levocetirizine at higher concentrations can reduce the release of GM-CSF and IL-8 from A549 cells stimulated with IL-1beta.	levocetirizine	40-54	C-X-C motif chemokine ligand 8	Homo sapiens	117-121
18926057-10	2008	Our results suggest that cetirizine and levocetirizine at higher concentrations can reduce the release of GM-CSF and IL-8 from A549 cells stimulated with IL-1beta.	levocetirizine	40-54	interleukin 1 beta	Homo sapiens	154-162
18201439-1	2007	Levocetirizine is the most recent antihistamine available in the United States and is indicated for the symptomatic treatment of allergic rhinitis (AR; seasonal [SAR] and perennial [PAR]) and chronic idiopathic urticaria (CIU).	levocetirizine	0-14	sarcosine dehydrogenase	Homo sapiens	162-165
18201439-1	2007	Levocetirizine is the most recent antihistamine available in the United States and is indicated for the symptomatic treatment of allergic rhinitis (AR; seasonal [SAR] and perennial [PAR]) and chronic idiopathic urticaria (CIU).	levocetirizine	0-14	nuclear receptor subfamily 1 group I member 2	Homo sapiens	182-185
18201439-7	2007	Several large well-controlled clinical trials in adults and children aged 6-12 years have shown levocetirizine to be consistently efficacious and well tolerated in relieving the symptoms of SAR, PAR, and PER and CIU.	levocetirizine	96-110	sarcosine dehydrogenase	Homo sapiens	190-193
18201439-7	2007	Several large well-controlled clinical trials in adults and children aged 6-12 years have shown levocetirizine to be consistently efficacious and well tolerated in relieving the symptoms of SAR, PAR, and PER and CIU.	levocetirizine	96-110	nuclear receptor subfamily 1 group I member 2	Homo sapiens	195-198
18034979-8	2007	Of the 40 cytokines studied, levocetirizine (1 microM) was found to enhance the release of tissue inhibitor of metalloproteinases 1 and 4, matrix metalloproteinase 9, and heparin-binding epidermal growth factor and to attenuate the production of interleukins (IL)-1 beta and IL-7 and stem cell factor in lipopolysaccharide-stimulated human eosinophils.	levocetirizine	29-43	matrix metallopeptidase 9	Homo sapiens	91-165
18034979-8	2007	Of the 40 cytokines studied, levocetirizine (1 microM) was found to enhance the release of tissue inhibitor of metalloproteinases 1 and 4, matrix metalloproteinase 9, and heparin-binding epidermal growth factor and to attenuate the production of interleukins (IL)-1 beta and IL-7 and stem cell factor in lipopolysaccharide-stimulated human eosinophils.	levocetirizine	29-43	heparin binding EGF like growth factor	Homo sapiens	171-210
18034979-8	2007	Of the 40 cytokines studied, levocetirizine (1 microM) was found to enhance the release of tissue inhibitor of metalloproteinases 1 and 4, matrix metalloproteinase 9, and heparin-binding epidermal growth factor and to attenuate the production of interleukins (IL)-1 beta and IL-7 and stem cell factor in lipopolysaccharide-stimulated human eosinophils.	levocetirizine	29-43	interleukin 1 beta	Homo sapiens	246-270
18034979-8	2007	Of the 40 cytokines studied, levocetirizine (1 microM) was found to enhance the release of tissue inhibitor of metalloproteinases 1 and 4, matrix metalloproteinase 9, and heparin-binding epidermal growth factor and to attenuate the production of interleukins (IL)-1 beta and IL-7 and stem cell factor in lipopolysaccharide-stimulated human eosinophils.	levocetirizine	29-43	interleukin 7	Homo sapiens	275-279
17107400-2	2006	OBJECTIVES: To determine if 6 weeks of therapy with levocetirizine 5 mg once daily would also induce any decrease in serum levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, endothelial leucocyte adhesion molecule-1 (ELAM-1) or P-selectin in subjects with CU and chronic autoimmune urticaria.	levocetirizine	52-66	intercellular adhesion molecule 1	Homo sapiens	133-166
17394131-8	2007	The MDR1 mRNA and P-gp levels in Caco-2 cells were increased by 100 microM R-cetirizine and decreased by 100 microM S-cetirizine.	levocetirizine	75-87	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
17394131-8	2007	The MDR1 mRNA and P-gp levels in Caco-2 cells were increased by 100 microM R-cetirizine and decreased by 100 microM S-cetirizine.	levocetirizine	75-87	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
17394131-9	2007	These results suggest that R-cetirizine up-regulates MDR1 expression while S-cetirizine down-regulates MDR1 expression.	levocetirizine	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
17107400-2	2006	OBJECTIVES: To determine if 6 weeks of therapy with levocetirizine 5 mg once daily would also induce any decrease in serum levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, endothelial leucocyte adhesion molecule-1 (ELAM-1) or P-selectin in subjects with CU and chronic autoimmune urticaria.	levocetirizine	52-66	selectin E	Homo sapiens	246-252
17107400-2	2006	OBJECTIVES: To determine if 6 weeks of therapy with levocetirizine 5 mg once daily would also induce any decrease in serum levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, endothelial leucocyte adhesion molecule-1 (ELAM-1) or P-selectin in subjects with CU and chronic autoimmune urticaria.	levocetirizine	52-66	selectin P	Homo sapiens	257-267
17107400-7	2006	RESULTS: After levocetirizine therapy CAM levels decreased in patients with CU, significantly in the cases of ELAM-1 and P-selectin.	levocetirizine	15-29	selectin E	Homo sapiens	110-116
17107400-7	2006	RESULTS: After levocetirizine therapy CAM levels decreased in patients with CU, significantly in the cases of ELAM-1 and P-selectin.	levocetirizine	15-29	selectin P	Homo sapiens	121-131
16970513-1	2006	BACKGROUND AND OBJECTIVES: Desloratadine and levocetirizine are histamine H(1) receptor antagonists (antihistamines) that were launched in the UK in 2001.	levocetirizine	45-59	histamine receptor H1	Homo sapiens	64-87
17063735-0	2006	The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine.	levocetirizine	130-144	vascular cell adhesion molecule 1	Homo sapiens	45-78
17063735-4	2006	The inhibitory effect of the selective H1-antagonist levocetirizine (0.01-10.0 microM) on VCAM-1 expression was also tested.	levocetirizine	53-67	vascular cell adhesion molecule 1	Homo sapiens	90-96
17063735-6	2006	To evaluate the ability of levocetirizine to downregulate VCAM-1 expression, fibroblasts were stimulated with histamine (1000 microM) or IL-4 + TNF-alpha (5 ng/mL), in the presence of the drug (0.01-10.0 microM).	levocetirizine	27-41	vascular cell adhesion molecule 1	Homo sapiens	58-64
17063735-7	2006	The histamine-induced VCAM-1 expression was effectively inhibited by levocetirizine (0.1-10.0 microM) (p < 0.05).	levocetirizine	69-83	vascular cell adhesion molecule 1	Homo sapiens	22-28
17063735-9	2006	CONCLUSIONS: Histamine upregulates VCAM-1 expression on nasal polyp-derived fibroblasts and this phenomenon, relevant to allergic late-phase inflammation, is effectively inhibited by levocetirizine.	levocetirizine	183-197	vascular cell adhesion molecule 1	Homo sapiens	35-41
16740020-1	2006	Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU).	levocetirizine	0-14	histamine receptor H1	Homo sapiens	52-75
16740020-1	2006	Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU).	levocetirizine	16-21	histamine receptor H1	Homo sapiens	52-75
15196286-13	2004	Levocetirizine significantly reduced eosinophils (P=0.029), neutrophils (P=0.005), IL-4 (P=0.041), and IL-8 (P=0.02), whereas desloratadine diminished IL-4 only (P=0.044).	levocetirizine	0-14	interleukin 4	Homo sapiens	83-87
16275616-10	2005	RESULTS: Desloratadine and levocetirizine treatment induced significant symptom relief and significant reduction of IL-4.	levocetirizine	27-41	interleukin 4	Homo sapiens	116-120
18360569-7	2005	Levocetirizine is a potent histamine H(1)-receptor antagonist with proven efficacy in both SAR and PAR, and it is the best studied therapeutic option in persistent AR.	levocetirizine	0-14	histamine receptor H1	Homo sapiens	27-50
18360569-10	2005	Thus, levocetirizine is the first tested standard treatment for PER using ARIA classification, and shows prompt short-term and long-term relief of symptoms, improves patients" QoL, and provides economic benefits to employers and the society.	levocetirizine	6-20	endothelial cell surface expressed chemotaxis and apoptosis regulator	Homo sapiens	74-78
15298570-9	2004	In vitro, endothelial cells produced eotaxin mRNA and protein product in a dose- and time-dependent fashion following incubation with histamine, an effect that was blocked by levocetirizine.	levocetirizine	175-189	C-C motif chemokine ligand 11	Homo sapiens	37-44
15312146-13	2004	The fact that levocetirizine is a substrate of P-gp, although weak in an in vitro model, could contribute to prevent drug penetration into the brain, whereas it is unlikely to be of any clinical relevance for P-gp-mediated drug interactions.	levocetirizine	14-28	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
16120090-0	2005	A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions.	levocetirizine	20-34	vascular cell adhesion molecule 1	Homo sapiens	67-100
16120090-2	2005	OBJECTIVE: Here, the inhibitory effect of levocetirizine on eosinophil adhesion to recombinant human vascular cell adhesion molecule-1 (rhVCAM)-1 was examined under conditions of shear stress using an in vitro model of the post-capillary venules.	levocetirizine	42-56	vascular cell adhesion molecule 1	Homo sapiens	101-134
16120090-11	2005	CONCLUSION: Physiologically relevant concentrations of levocetirizine inhibit resting and GM-CSF-stimulated firm eosinophil adhesion to rhVCAM-1 under flow conditions.	levocetirizine	55-69	colony stimulating factor 2	Homo sapiens	90-96
15536428-11	2004	Levocetirizine at higher doses also reduced intercellular adhesion molecule 1, CCL5/RANTES, and GM-CSF release induced solely by IFN-gamma.	levocetirizine	0-14	intercellular adhesion molecule 1	Homo sapiens	44-77
15536428-11	2004	Levocetirizine at higher doses also reduced intercellular adhesion molecule 1, CCL5/RANTES, and GM-CSF release induced solely by IFN-gamma.	levocetirizine	0-14	C-C motif chemokine ligand 5	Homo sapiens	79-83
15536428-11	2004	Levocetirizine at higher doses also reduced intercellular adhesion molecule 1, CCL5/RANTES, and GM-CSF release induced solely by IFN-gamma.	levocetirizine	0-14	C-C motif chemokine ligand 5	Homo sapiens	84-90
15536428-11	2004	Levocetirizine at higher doses also reduced intercellular adhesion molecule 1, CCL5/RANTES, and GM-CSF release induced solely by IFN-gamma.	levocetirizine	0-14	colony stimulating factor 2	Homo sapiens	96-102
15536428-11	2004	Levocetirizine at higher doses also reduced intercellular adhesion molecule 1, CCL5/RANTES, and GM-CSF release induced solely by IFN-gamma.	levocetirizine	0-14	interferon gamma	Homo sapiens	129-138
15196286-13	2004	Levocetirizine significantly reduced eosinophils (P=0.029), neutrophils (P=0.005), IL-4 (P=0.041), and IL-8 (P=0.02), whereas desloratadine diminished IL-4 only (P=0.044).	levocetirizine	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	103-107
15196286-13	2004	Levocetirizine significantly reduced eosinophils (P=0.029), neutrophils (P=0.005), IL-4 (P=0.041), and IL-8 (P=0.02), whereas desloratadine diminished IL-4 only (P=0.044).	levocetirizine	0-14	interleukin 4	Homo sapiens	151-155
32572668-11	2020	At the histamine-binding site in hH1R, the distinct interactions established between the phenyl and chlorophenyl moieties of the two enantiomers with the amino acids lining up the pocket and between their free carboxylates and Lys179 in the second extracellular loop account for the improved pharmacological profile of (R)-cetirizine.	levocetirizine	319-333	histamine receptor H1	Homo sapiens	33-37
12190657-0	2002	Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells.	levocetirizine	15-29	C-C motif chemokine ligand 11	Homo sapiens	38-45
12190657-8	2002	Pre-incubation of eosinophils with cetirizine or levocetirizine dose-dependently inhibited eosinophil TEM to eotaxin through both HMVEC-d or HMVEC-l with total inhibition of eotaxin-induced TEM observed at 10-8 m for HMVEC-d and 10-7 m for HMVEC-l.	levocetirizine	49-63	C-C motif chemokine ligand 11	Homo sapiens	109-116
12190657-8	2002	Pre-incubation of eosinophils with cetirizine or levocetirizine dose-dependently inhibited eosinophil TEM to eotaxin through both HMVEC-d or HMVEC-l with total inhibition of eotaxin-induced TEM observed at 10-8 m for HMVEC-d and 10-7 m for HMVEC-l.	levocetirizine	49-63	C-C motif chemokine ligand 11	Homo sapiens	174-181
12190657-12	2002	CONCLUSION: Levocetirizine inhibits eotaxin-induced eosinophil TEM through both dermal and lung microvascular endothelial cells suggesting that, like cetirizine, levocetirizine has potential anti-inflammatory effects.	levocetirizine	12-26	C-C motif chemokine ligand 11	Homo sapiens	36-43
12190657-12	2002	CONCLUSION: Levocetirizine inhibits eotaxin-induced eosinophil TEM through both dermal and lung microvascular endothelial cells suggesting that, like cetirizine, levocetirizine has potential anti-inflammatory effects.	levocetirizine	162-176	C-C motif chemokine ligand 11	Homo sapiens	36-43
11576078-7	2001	Levocetirizine reduced the flare, wheal, and itch by 60%, 68%, and 91%, respectively (all P<0.001, Student"s t-test for paired data).	levocetirizine	0-14	itchy E3 ubiquitin protein ligase	Homo sapiens	45-49
34464376-12	2021	She was successfully treated for Clostridioides difficile with metronidazole and probiotics, and had complete clinical remission of the Wells syndrome with mometasone furoate cream and levocetirizine.	levocetirizine	185-199	Src homology 2 domain containing E	Homo sapiens	0-3
14505791-1	2003	The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.	levocetirizine	90-104	histamine receptor H1	Homo sapiens	11-34
14505791-7	2003	Moreover, the non-renal (mostly hepatic) clearance of levocetirizine is also significantly lower than that of dextrocetirizine (11.8 mL min(-1) vs. 29.2 mL min(-1)).	levocetirizine	54-68	CD59 molecule (CD59 blood group)	Homo sapiens	136-142
14505791-7	2003	Moreover, the non-renal (mostly hepatic) clearance of levocetirizine is also significantly lower than that of dextrocetirizine (11.8 mL min(-1) vs. 29.2 mL min(-1)).	levocetirizine	54-68	CD59 molecule (CD59 blood group)	Homo sapiens	156-162
14520518-12	2003	Levocetirizine was more consistent in its effects, mean reductions in wheal, flare and itch being 51%, 67% 78% respectively (all P < 0.001).	levocetirizine	0-14	itchy E3 ubiquitin protein ligase	Homo sapiens	87-91
14520518-13	2003	CONCLUSIONS: A single dose of 5 mg levocetirizine produced more consistent and greater inhibitory effects on histamine-induced wheal, flare and itch than did 5 mg desloratadine.	levocetirizine	35-49	itchy E3 ubiquitin protein ligase	Homo sapiens	144-148
12787835-7	2003	The present results show that cetirizine and levocetirizine are selective competitive but slowly reversible histamine H(1) receptor antagonists.	levocetirizine	45-59	histamine H1 receptor	Cavia porcellus	108-131
12685505-0	2002	Blood distribution of levocetirizine, a new non-sedating histamine H1-receptor antagonist, in humans.	levocetirizine	22-36	histamine receptor H1	Homo sapiens	57-78
33100209-1	2021	BACKGROUND: For the first time, the inhibitory effects on human salivary alpha-amylase activity of the antiinflammatory drugs: indomethacin, diclofenac sodium, ketoprofen, diclofenac potassium, diclofenac, triamcinolone acetonide and the antihistamines drugs: levocetirizine dihydrochloride, desloratadine, cycloheptadine hydrochloride has been investigated to confirm the other properties of these drugs.	levocetirizine	260-290	amylase alpha 1A	Homo sapiens	64-86
31714659-0	2020	Levocetirizine for the Treatment of Itch in Psoriasis Patients: An Open-label Pilot Study in a Real-world Setting.	levocetirizine	0-14	itchy E3 ubiquitin protein ligase	Homo sapiens	36-40
32156129-8	2020	The relative mRNA expressions of COX-2, PGF2a, PTGDS, GPR44, and AKT showed significant differences in different levocetirizine hydrochloride groups (the F values were 1.97, 3.66, 2.17, 2.66, and 7.32, respectively; all P<0.05), whereas the mRNA expressions of PGE2 and GSK3beta showed no significant difference (F=0.87, F=1.19, respectively; both P>0.05).	levocetirizine	113-141	prostaglandin-endoperoxide synthase 2	Homo sapiens	33-38
32156129-8	2020	The relative mRNA expressions of COX-2, PGF2a, PTGDS, GPR44, and AKT showed significant differences in different levocetirizine hydrochloride groups (the F values were 1.97, 3.66, 2.17, 2.66, and 7.32, respectively; all P<0.05), whereas the mRNA expressions of PGE2 and GSK3beta showed no significant difference (F=0.87, F=1.19, respectively; both P>0.05).	levocetirizine	113-141	prostaglandin D2 synthase	Homo sapiens	47-52
32156129-8	2020	The relative mRNA expressions of COX-2, PGF2a, PTGDS, GPR44, and AKT showed significant differences in different levocetirizine hydrochloride groups (the F values were 1.97, 3.66, 2.17, 2.66, and 7.32, respectively; all P<0.05), whereas the mRNA expressions of PGE2 and GSK3beta showed no significant difference (F=0.87, F=1.19, respectively; both P>0.05).	levocetirizine	113-141	prostaglandin D2 receptor 2	Homo sapiens	54-59
32156129-8	2020	The relative mRNA expressions of COX-2, PGF2a, PTGDS, GPR44, and AKT showed significant differences in different levocetirizine hydrochloride groups (the F values were 1.97, 3.66, 2.17, 2.66, and 7.32, respectively; all P<0.05), whereas the mRNA expressions of PGE2 and GSK3beta showed no significant difference (F=0.87, F=1.19, respectively; both P>0.05).	levocetirizine	113-141	AKT serine/threonine kinase 1	Homo sapiens	65-68
32156129-12	2020	CONCLUSIONS: Levocetirizine hydrochloride may promote the growth and proliferation of hDPC in vitro by inhibiting the PGD2-GPR44 pathway and activating the AKT signaling pathway.	levocetirizine	13-41	decapping mRNA 2	Homo sapiens	86-90
32156129-12	2020	CONCLUSIONS: Levocetirizine hydrochloride may promote the growth and proliferation of hDPC in vitro by inhibiting the PGD2-GPR44 pathway and activating the AKT signaling pathway.	levocetirizine	13-41	prostaglandin D2 receptor 2	Homo sapiens	123-128
32156129-12	2020	CONCLUSIONS: Levocetirizine hydrochloride may promote the growth and proliferation of hDPC in vitro by inhibiting the PGD2-GPR44 pathway and activating the AKT signaling pathway.	levocetirizine	13-41	AKT serine/threonine kinase 1	Homo sapiens	156-159
32467688-0	2020	The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria - a pilot study.	levocetirizine	14-28	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	102-107
32467688-0	2020	The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria - a pilot study.	levocetirizine	14-28	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	112-117
32467688-11	2020	Conclusions: The effectiveness of levocetirizine and montelukast in treating CAU may be partly related to the reduction of COX-1 and COX-2 serum level and tissue expression, but further studies on a larger group of patients are needed to support this observation.	levocetirizine	34-48	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	123-128
32467688-11	2020	Conclusions: The effectiveness of levocetirizine and montelukast in treating CAU may be partly related to the reduction of COX-1 and COX-2 serum level and tissue expression, but further studies on a larger group of patients are needed to support this observation.	levocetirizine	34-48	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	133-138
31183190-3	2019	Levocetirizine is a second generation H1 antihistamine with anti-inflammatory and IL-8 suppression properties.	levocetirizine	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	82-86